Phase 0.5? FDA Guidance Allows Pre-Clinical Micro-Dose Studies In Human Subjects
This article was originally published in The Pink Sheet Daily
Aimed at academic researchers, FDA's final guidance permits study of the mechanism of action of new agents at low doses.
You may also be interested in...
The agency believes that industry has not taken full advantage of the flexibility provided in investigational new drug regulations. The draft guidance advises sponsors on how to proceed with early Phase I, short-term "microdosing" studies.
Dr. Reddy's, GSK, Ranbaxy and UCB among manufacturers that could see prices reduced under government order that reflects issues raised in Gleevec patent dispute.
Indian regulators threaten compulsory licensing of the oncologic, but Novartis says it has no plans to end its bid for patent protection.